Latest revenue
$5.1M
as of 2026-03-31
Latest net income
$-7.7M
as of 2026-03-31
Net margin
-149.4%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $8.5M
- Enterprise value
- $8.5M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $7.95
- 52-wk low
- $0.55
- Beta
- —
- Shares out
- 13.9M
5-year trend
What this company does
Item 1. Business. Overview and Mission We are a revenue stage medical technology and healthcare services company that features a comprehensive suite of proprietary oral appliances and therapeutic treatments. Our products non-surgically treat certain maxillofacial and developmental abnormalities of the mouth and jaws that are closely associated with breathing and sleep disorders such as mild to severe obstructive sleep apnea (known as OSA) and snoring in adults. We call the use of our appliances coupled with specific therapeutic treatment protocols The Vivos Method. The Vivos Method is estimated to be indicated and potentially effective (within the scope of the FDA cleared uses) in…
AI summary unavailable — showing raw filing excerpt
Generated from VVOS's filing dated 2026-04-15
Key risks
Item 1A. Risk Factors. Investing in our common stock is highly speculative and involves a significant degree of risk. Before you invest in our securities, you should give careful consideration to the following risk factors, in addition to the other information included in this Annual Report on Form 10-K, including our financial statements and related notes, before deciding whether to invest in our securities. The occurrence of any of the adverse developments described in the following risk factors could materially and adversely harm our business, financial condition, results of operations or prospects. In that case, the trading price of our common stock could decline, and you may lose all…
AI summary unavailable — showing raw filing excerpt
Generated from VVOS's filing dated 2026-04-15
Profitability
Gross margin
60.4%
0.7%Operating margin
-114.1%
53.5%Net margin
-121.4%
63.8%Return on equity
1420.8%
1114.8%Return on assets
-84.2%
15.5%Leverage
Debt / equity
-17.88×
2040.3%Long-term debt / equity
-0.31×
Debt / assets
105.9%
120.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $5.1M | +70.5% | $-7.7M | -98.8% | -149.4% |
Q4 2025 2025-12-31 | $3.8M | +3.4% | $-6.9M | -143.8% | -180.3% |
Q3 2025 2025-09-30 | $6.8M | +75.7% | $-5.4M | -106.4% | -79.6% |
Q2 2025 2025-06-30 | $3.8M | -5.8% | $-5.0M | -159.7% | -131.2% |
Q1 2025 2025-03-31 | $3.0M | -11.8% | $-3.9M | -2.7% | -128.1% |
Q4 2024 2024-12-31 | $3.7M | — | $-2.8M | — | -76.4% |
Q3 2024 2024-09-30 | $3.9M | +16.9% | $-2.6M | -25.0% | -67.8% |
Q2 2024 2024-06-30 | $4.1M | +19.4% | $-1.9M | +65.1% | -47.6% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on VVOS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$7.2M
Insider selling
$0
Net activity
+$7.2M
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns VVOS
Institutional value
$226.3K
Total shares held
194.6K
Distinct holders
12
-6 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | COMMONWEALTH EQUITY SERVICES, LLC | 42.5K | $50.1K | +2.0K (+4.9%) | Added |
| 2 | Centurion Wealth Management LLC | 35.7K | $42.1K | — | New |
| 3 | B. Riley Wealth Advisors, Inc. | 38.1K | $41.5K | -5.5K (-12.6%) | Trimmed |
| 4 | BlackRock, Inc. | 27.8K | $32.8K | +0 (+0.0%) | No change |
| 5 | Sequoia Financial Advisors, LLC | 24.0K | $28.3K | — | New |
| 6 | Acorn Wealth Advisors, LLC | 14.8K | $17.4K | +0 (+0.0%) | No change |
| 7 | UBS Group AG | 11.0K | $13.0K | -1.6K (-12.9%) | Trimmed |
| 8 | SIGNATUREFD, LLC | 547 | $645 | +0 (+0.0%) | No change |
| 9 | Blue Trust, Inc. | 160 | $189 | +0 (+0.0%) | No change |
| 10 | Kozak & Associates, Inc. | 49 | $60 | +0 (+0.0%) | No change |
| 11 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 3 | $4 | — | New |
| 12 | CITIGROUP INC | 1 | $1 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once VVOS's latest filing finishes processing.